Answers are grounded in this paper and cite their sources.
Analysis reveals effective management for adverse events in patients treated with repotrectinib, indicating potential benefits in clinical settings.
Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
No takes yet. Share an insight, caveat, or question.
Drilon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: